secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harmony Biosciences Holdings, Inc. (HRMY)
CIK:        0001802665
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001558370-25-000157
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harmony Biosciences: Q4 WAKIX revenue ~$201M, FY2024 ~$714M; guides 2025 $820-860M
--------------------------------------------------------------------------------

- Preliminary Q4 2024 net product revenue ~$201M (vs $168.4M Q4 2023); FY2024 ~$714M (vs $582M, +23% YoY).
- 2025 net revenue guidance of $820-860M, implying continued growth toward $1B+ opportunity.
- Pipeline catalysts: FDA decision on pitolisant sNDA for idiopathic hypersomnia expected Q1 2025; potential approval in 2025.
- Phase 3 topline data for ZYN002 in Fragile X syndrome expected Q3 2025; Pitolisant-HD Phase 3 in narcolepsy to start Q4 2025.
- Average patients on WAKIX increased to ~7,100 in Q4 2024, up ~300 sequentially.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802665/000155837025000157/0001558370-25-000157-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802665/000155837025000157/hrmy-20250113x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-000157

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer